Searched for
BIOPHARMA INDIA GROWTH
L’Oréal adds Innovist to cart; HealthQuad's new fundHappy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...- HealthQuad raises Rs 550 crore, eyes Rs 1,700 crore fundHealthQuad has secured Rs 550 crore for its third fund. The venture capital firm aims to raise Rs 1,700 crore to back early-growth companie...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Piyush Goyal meets Ernst & Young CEO, discusses India's role in global supply chainsUnion Minister Piyush Goyal said he held a meeting with Janet Truncale, Global Chair and CEO of EY, to discuss India's growing role in glob...
- India steers boat through a risky channel between war clouds and El NinoIndia faces a challenging global economic outlook for 2026-27. Geopolitical tensions and volatile oil prices are key concerns. However, Ind...
- India Pharma 2026 event: Nadda lays out road map for India to take global pharma leadership roleIndia Pharma Conference: India is set to become a global leader in advanced medicines like biologics and biosimilars, Union Minister J P Na...
- Stocks in news: TCS, HDFC Bank, ITC Hotels, Hyundai India, Adani EnterprisesMarkets surged for the fourth consecutive session, buoyed by favorable geopolitical cues. Key stocks like TCS, HDFC Bank, ITC Hotels, Hyund...
- Budget 2026 bets on biopharma, SME capital to drive resilient growth: Industry leadersThe Union Budget 2026-27 focuses on fortifying the Indian economy against global volatility through strategic investments in technology, he...
- Budget to boost economy, enhance India's global competitiveness: India IncIndia Inc has welcomed the Union Budget 2026-27. Industry leaders believe it is a budget for the real economy. It focuses on enhancing Indi...
- Budget 2026: Sitharaman launches 'Biopharma Shakti' with a Rs 10,000-crore bet to heal India, power manufacturingUnion Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceut...
- Budget 2026: Sitharaman proposes Rs 10,000-crore Biopharma Shakti scheme to boost biopharma manufacturingThe proposed fund aims to position India as a global biopharma manufacturing hub
- Budget 2026: Sitharaman’s six-point plan to propel India’s next growth phaseUnion Budget 2026: Finance Minister Nirmala Sitharaman has presented a six-point plan to boost India's economy. The strategy prioritizes ma...
- US life sciences firm Cytiva opens new manufacturing site in PuneUS-based sciences company Cytiva has opened a new manufacturing facility and Experience Centre in Pune, India. The facility will double Cyt...
- India emerging as favourable destination to conduct global clinical trials: ReportThe joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...
- Dr. Reddy's inks pact with Singapore firm Prestige BioPharma to commercialise Trastuzumab biosimilar in select countriesHyderabad, Dec 9- Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two comp...
- Syngene's CEO Jonathan Hunt says India now offers intellectual arbitrage to firms“A young scientist joining a company like Syngene can travel the world scientifically without ever having to leave Bengaluru. It provides o...
- Pharma sector needs global collaboration: Industry leaders, government officialsAhead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...
- India can become innovation hub for bio-pharma: BCG reportEmerging markets will drive 70% of growth in the pharma industry and India will require supportive policies to leverage the BioPharma.
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
Load More
